Published in Oncotarget on October 04, 2016
Circulating mutational portrait of cancer: manifestation of aggressive clonal events in both early and late stages. J Hematol Oncol (2017) 0.75
Liquid biopsies in lung cancer-time to implement research technologies in routine care? Ann Transl Med (2017) 0.75
Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med (2009) 46.35
Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med (2012) 44.56
EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A (2004) 33.85
Index for rating diagnostic tests. Cancer (1950) 27.09
Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med (2014) 16.83
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med (2015) 13.08
The life history of 21 breast cancers. Cell (2012) 10.59
Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med (2014) 8.36
Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol (2013) 7.97
Spatial and temporal diversity in genomic instability processes defines lung cancer evolution. Science (2014) 5.63
DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res (2001) 5.45
Liquid biopsies: genotyping circulating tumor DNA. J Clin Oncol (2014) 4.76
Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing. Science (2014) 4.28
Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assay. Clin Cancer Res (2011) 4.16
Clonal evolution in breast cancer revealed by single nucleus genome sequencing. Nature (2014) 4.13
Prospective Validation of Rapid Plasma Genotyping for the Detection of EGFR and KRAS Mutations in Advanced Lung Cancer. JAMA Oncol (2016) 2.60
Use of research biopsies in clinical trials: are risks and benefits adequately discussed? J Clin Oncol (2012) 2.43
Detection and Dynamic Changes of EGFR Mutations from Circulating Tumor DNA as a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line Intercalated Erlotinib and Chemotherapy. Clin Cancer Res (2015) 1.59
Deciphering intratumor heterogeneity and temporal acquisition of driver events to refine precision medicine. Genome Biol (2014) 1.44
Systematic pan-cancer analysis of tumour purity. Nat Commun (2015) 1.35
Circulating tumour cells and cell-free DNA as tools for managing breast cancer. Nat Rev Clin Oncol (2013) 1.33
The clinical utilization of circulating cell free DNA (CCFDNA) in blood of cancer patients. Int J Mol Sci (2013) 1.25
Tumor mutation burden forecasts outcome in ovarian cancer with BRCA1 or BRCA2 mutations. PLoS One (2013) 1.11
Cell-Free DNA Next-Generation Sequencing in Pancreatobiliary Carcinomas. Cancer Discov (2015) 1.01
Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapies. Oncotarget (2015) 0.92
Detection rate of actionable mutations in diverse cancers using a biopsy-free (blood) circulating tumor cell DNA assay. Oncotarget (2016) 0.88
Prospective blinded study of somatic mutation detection in cell-free DNA utilizing a targeted 54-gene next generation sequencing panel in metastatic solid tumor patients. Oncotarget (2015) 0.87
Circulating Cell-Free Tumor DNA Analysis of 50 Genes by Next-Generation Sequencing in the Prospective MOSCATO Trial. Clin Cancer Res (2016) 0.87
BRAF mutation testing with a rapid, fully integrated molecular diagnostics system. Oncotarget (2015) 0.83
Clinical Application of Liquid Biopsies. JAMA Oncol (2016) 0.81